

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Cell division cycle 34 homolog (CDC34); S-phase kinase-associated protein 2 (SKP2)	An <i>in vitro</i> study suggests inhibiting CDC34 could help treat cancer. An <i>in vitro</i> screen of ubiquitinating activity identified an inhibitor of CDC34, one of the components of the multisubunit SKP2 ubiquitin ligase complex. In prostate cancer cells, the inhibitor decreased cell proliferation compared with vehicle. Next steps could include developing more potent inhibitors. Celgene Corp. is not pursuing this molecule or target. SciBX 4(28); doi:10.1038/scibx.2011.788 Published online July 21, 2011	Unpatented; licensing status not applicable	<p>Ceccarelli, D.F. <i>et al. Cell</i>; published online June 16, 2011; doi:10.1016/j.cell.2011.05.039</p> <p>Contact: Frank Sichi, University of Toronto, Toronto, Ontario, Canada e-mail: sichi@lunenfeld.ca</p> <p>Contact: Mike Tyers, The University of Edinburgh, Edinburgh, U.K. e-mail: m.tyers@ed.ac.uk</p> <p>Contact: David R. Webb, Celgene Corp., San Diego, Calif. e-mail: dwebb@celgene.com</p>